LGMN and neoplasm: As reported in our previous study, Legumain-targeting NPs enhanced solid-tumor penetration compared with non-targeting NPs; treatment of tumor-bearing mice with RR-11a-coupled NPs encapsulating doxorubicin resulted in improved tumor selectivity and drug sensitivity, leading to completely inhibition of tumor growth.